Comparative effectiveness in multiple sclerosis: A methodological comparison.
Izanne RoosIbrahima DioufSifat SharminDana HorákováEva Kubala HavrdovaFrancesco PattiVahid ShaygannejadSerkan OzakbasGuillermo IzquierdoSara EichauMarco OnofrjAlessandra LugaresiRaed AlroughaniAlexandre PratMarc GirardPierre DuquetteMurat TerziCavit BozFrancois Grand'MaisonPatrizia SolaDiana FerraroPierre GrammondRecai TurkogluKatherine BuzzardOlga SkibinaBassem YamouAyse AltintasOliver GerlachVincent van PeschYolanda BlancoDavide MaimoneJeannette Lechner-ScottRoberto BergamaschiRana KarabudakChris McGuiganElisabetta CartechiniMichael Harry BarnettStella HughesMaria José SaClaudio SolaroCristina Ramo-TelloSuzanne HodgkinsonDaniele SpitaleriAysun SoysalThor PetersenFranco GranellaKoen de GansPamela McCombeRadek AmpapaBart Van WijmeerschAnneke Van Der WaltHelmut ButzkuevenJulie PrevostJose Luis Sanchez-MenoyoGuy LaureysRiadh GouiderTamara Castillo TriviñoOrla GrayEduardo Aguera-MoralesAbdullah Al-AsmiCameron ShawNorma DeriTalal Al-HarbiYara Dadalti FragosoTunde CsepanyAngel Perez SempereIrene Trevino-FrenkJan SchepelFraser MooreCharles MalpasTomas KalincikPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
The relative effectiveness of two therapies can be efficiently compared by either marginal structural models or propensity score matching when applied in clearly defined clinical contexts and in sufficiently powered cohorts.